Case report: A durable response to Anastrozole re-challenge with Everolimus in a patient with advanced-stage estrogen receptor-positive breast cancer
Main Article Content
Keywords
stage IV ER+ breast cancer, mTOR inhibitor, treatment rechallenge
Abstract
Estrogen receptor-positive breast cancer is a heterogeneous disease characterized by its dependence on estrogen for growth and progression. Although hormonal therapy remains the cornerstone of treatment, many patients eventually develop resistance, leading to recurrence and disease progression. This case report describes a durable response to a rechallenge with Anastrozole (Arimidex) in combination with Everolimus (Afinitor), an mTOR inhibitor, in a patient with advanced (stage IV) ER+ metastatic breast cancer.
References
2. Jansen MP, et al. Mechanisms of resistance to endocrine therapy in breast cancer: the role of the tumor microenvironment. Eur J Cancer. 2017;83:120-130.
3. D’Angelo SP, et al. The role of mTOR inhibitors in the treatment of breast cancer. Oncologist. 2015;20(9):973-982.
4. Andre F, et al. Targeting the PI3K/mTOR pathway in breast cancer: a review of the literature. Cancer Treat Rev. 2014;40(5):612-619.
5. Mardini S, et al. Combination therapy for ER+ breast cancer: a review of current strategies and future directions. Cancer Treat Rev. 2020;90:102103.
Sweeney C, et al. Re-challenge with aromatase inhibitors and clinical outcomes in recurrent ER+ breast cancer. Breast Cancer Res Treat. 2018;169(1):27-34.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.